Regional Dermatology Billing Groups Are Quietly Exiting Prior Authorization Work
The Quiet Exit from a Thankless Task
Prior authorization has long been the administrative equivalent of a toll booth that never opens on time. For dermatology billing groups operating at the regional level, the process of securing insurer approval before a patient receives a biologic prescription, a laser procedure, or a specialty diagnostic has become so resource-intensive that a growing number of these groups are simply walking away from it entirely. They are not closing up shop – they are restructuring their service offerings to exclude prior authorization work from their contracts.
The shift is happening without press releases or industry fanfare. Billing managers are quietly renegotiating client agreements, and dermatology practices are waking up to find that the vendor they relied on for prior authorization support is no longer offering that service. What looks like a niche operational change carries real consequences for patient access, practice revenue cycles, and the broader economics of specialty medical billing.
Why Prior Authorization Work Has Become Untenable
The math on prior authorization has never been favorable for billing groups. The labor required to chase down an approval for a single biologic drug – a category that now dominates dermatology prescribing for conditions like psoriasis, atopic dermatitis, and hidradenitis suppurativa – can run several hours per case. That includes gathering clinical documentation, submitting the initial request, fielding insurer denials, preparing peer-to-peer appeal documentation, and then managing the re-submission process. Regional billing groups typically operate on thin per-claim margins, and prior authorization generates no billable claim until it succeeds. Every hour spent on a denial that eventually gets overturned is an hour the billing group cannot recover financially.
The payer landscape has made this worse. Insurance companies have lengthened their review timelines, expanded their list of required supporting documentation, and introduced electronic portal systems that are frequently incompatible with smaller billing operations’ existing infrastructure. A regional billing group serving ten to twenty dermatology practices does not have the technology budget to maintain integrations with every payer portal that an insurer decides to mandate. The result is that prior authorization work has become disproportionately expensive relative to everything else these groups do.
What Practices Are Left to Handle
When a regional billing group exits prior authorization work, the responsibility does not disappear – it transfers. Dermatology practices absorb the function directly, which means clinical staff who were trained to manage patient care are now spending significant portions of their week on administrative appeals. Front-office coordinators with no billing background are suddenly responsible for understanding formulary tiers, step therapy requirements, and the specific language insurers want to see in a medical necessity letter.
Some practices are responding by hiring dedicated prior authorization specialists in-house. This is not a cheap solution. A full-time specialist capable of managing a high volume of dermatology biologics requests commands a salary that smaller practices struggle to justify against their existing overhead. The economics only work if the practice has enough high-cost prescription volume to keep that role fully occupied, which is not guaranteed for a mid-size regional practice.
Others are turning to tech-enabled prior authorization services – standalone platforms that use structured data and payer-specific logic to automate parts of the submission process. These platforms have attracted investment and attention in recent years, but they come with their own learning curve, and the automation still breaks down at the point where a human needs to write a clinical justification narrative or conduct a peer-to-peer call with an insurer’s medical director. No software currently handles that final step.
A third group of practices, particularly those in smaller markets without access to specialized staffing, is effectively going without. They are narrowing their treatment menus to avoid therapies that require prior authorization, steering patients toward older, cheaper agents that insurers approve without review. That is a clinical compromise that no one in the practice wants to make, but the administrative weight of the alternative is forcing the decision.
The Economics Behind the Exit
Regional billing groups did not enter prior authorization work willingly in the first place. Most took it on because practices demanded bundled services and were reluctant to split their billing operations across multiple vendors. Prior authorization came along with claims submission, payment posting, and denial management as part of a full revenue cycle package. The billing group absorbed the cost of the authorization work by pricing it into the overall contract rate.
That model held as long as prior authorization volume remained manageable and payer behavior remained predictable. Neither condition exists today. The approval requirements for dermatology biologics now involve multi-step documentation chains that can span weeks, and denial rates on first submission have climbed enough that a single drug authorization attempt frequently requires two or three rounds of insurer contact before a resolution. At some point, the bundled contract rate no longer covers the true cost of providing that service, and the billing group faces a choice between losing money on the contract or restructuring what the contract includes.
Most regional billing groups are choosing to restructure. They are carving out prior authorization as a separate, unbundled service with standalone pricing, or they are dropping it altogether and directing practices toward specialized authorization vendors. Either way, the era of prior authorization as a quiet line item buried inside a full-service billing agreement appears to be ending.
What Comes Next for Regional Billing Relationships
The dermatology billing market has been under consolidation pressure for several years, with larger national revenue cycle management companies acquiring regional groups and folding them into scaled operations. A regional billing group that can no longer offer prior authorization support becomes a less attractive standalone business, which accelerates that consolidation dynamic. Practices shopping for a new billing partner increasingly want to know upfront whether authorization support is included – and fewer regional groups can say yes.
The practices most exposed are those in suburban and rural markets where the roster of qualified billing partners is already limited. A dermatology group in a mid-sized city may have three or four regional billing vendors to choose from, and if two of them have exited prior authorization work, the options narrow quickly. The practice either accepts reduced services, pays a significant premium for the one vendor that still handles authorizations, or brings the function in-house at a cost that strains its operating budget.
What makes the situation particularly difficult to resolve is that prior authorization reform at the federal and state level has been discussed for years without producing the kind of structural change that would reduce the administrative burden. Legislation requiring faster insurer response times and limiting the scope of step therapy requirements has advanced in some states, but enforcement is inconsistent and payer behavior has changed slowly. Regional billing groups are not waiting for regulatory relief – they are making business decisions based on conditions as they exist today, not as advocates hope they will exist in the future. The practices left holding the authorization burden are the ones who will determine how long the current arrangement is sustainable.
